Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds antigen or epitope whose amino acid sequence is...
Reexamination Certificate
2011-07-19
2011-07-19
Saoud, Christine J (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds antigen or epitope whose amino acid sequence is...
C530S387900
Reexamination Certificate
active
07981419
ABSTRACT:
A method for treating a hypophosphatemic bone disease, such as X-linked hypophosphatemia (XLH). The method entails administering to a subject a pharmaceutical composition, which contains an antibody that binds to an FGF-23 polypeptide and a pharmaceutically acceptable carrier.
REFERENCES:
patent: 5585089 (1996-12-01), Queen et al.
patent: 5958879 (1999-09-01), Kopchick et al.
patent: 6001358 (1999-12-01), Black et al.
patent: 6617118 (2003-09-01), Roffler et al.
patent: 7094551 (2006-08-01), Zahradnik et al.
patent: 7223563 (2007-05-01), Econs et al.
patent: 7314618 (2008-01-01), Econs et al.
patent: 2002/0156001 (2002-10-01), Econs et al.
patent: 2004/0082506 (2004-04-01), Yamashita et al.
patent: 2004/0171825 (2004-09-01), Bougueleret et al.
patent: 2005/0048058 (2005-03-01), Yamazaki et al.
patent: 2006/0160181 (2006-07-01), Luethy et al.
patent: 2009/0110677 (2009-04-01), Yamashita et al.
patent: 2009/0148461 (2009-06-01), Yamazaki et al.
patent: 2418215 (2002-01-01), None
patent: 1446227 (2003-10-01), None
patent: 120694 (1984-10-01), None
patent: 125023 (1984-11-01), None
patent: 0314161 (1988-10-01), None
patent: 1466925 (2004-10-01), None
patent: 2188638 (1987-10-01), None
patent: S-61-178926 (1986-11-01), None
patent: H-02-117920 (1990-02-01), None
patent: WO 99/60017 (1999-11-01), None
patent: WO 00/10383 (2000-03-01), None
patent: WO 00/60085 (2000-10-01), None
patent: WO 00/73454 (2000-12-01), None
patent: WO 01/40466 (2001-06-01), None
patent: WO 01/42451 (2001-06-01), None
patent: WO 01/49740 (2001-07-01), None
patent: WO 01/60850 (2001-08-01), None
patent: WO 01/61007 (2001-08-01), None
patent: WO 01/66595 (2001-09-01), None
patent: WO 01/66596 (2001-09-01), None
patent: WO 02/08271 (2002-01-01), None
patent: WO 02/14504 (2002-02-01), None
patent: WO 02/76467 (2002-03-01), None
patent: WO 02/088358 (2002-11-01), None
patent: WO 03/057733 (2003-01-01), None
patent: WO 02/43478 (2004-05-01), None
patent: WO 2006/078072 (2006-07-01), None
patent: WO-2008/057683 (2008-05-01), None
patent: WO 2008/092019 (2008-07-01), None
Notice of Allowance for Korean Patent Application 10-2003-7001931 Dated Nov. 26, 2008.
Kenneth E. White et al., “Molecular cloning of a novel human UDP-GaINAc:polypeptide N-acetylgalactosaminyltransferase, GaINAc-T8, and analysis as a candidate autosomal dominant hypophophatemic rickets (ADHR) gene”, Gene 246 (2000), 347-356.
NCBI GenBank Accession No. NP—065689 (Mar. 25, 2007).
NCBI GenBank Accession No. NM—020638 (Mar. 25, 2007).
NCBI GenBank Accession No. AY566236 (Mar. 16, 2004).
Non-Final Office Action dated Dec. 29,2009, issued in related U.S. Appl. No. 10/500,296.
International Search Report of PCT Patent Application No. PCT/JP03/00017 dated Feb. 5, 2003—international, counterpart to related U.S. Appl. No. 10/500,296.
International Search Report of PCT Patent Application No. PCT/JP2008/052918 dated Mar. 13, 2008—international, counterpart to related U.S. Appl. No. 12/030,593.
Preissner et al., “Evaluation of the Immutopics Human FGF-23 (C-term) ELISA Kit”,Clinical Chemistry, vol. 52, No. 6, Suppl. S, Jun. 2006, p. A174.
Supplementary European Search Report EP 08 71 1707 dated Feb. 9, 2010.
Japanese Office Action Application No. JP 2003-558047 dated Jan. 26, 2010.
Takashi Shimada et al., “Possible Roles of Fibroblast Growth Factor 23 in Developing X-Linked Hypophosphatemia”, Clin. Pediatr. Endocrinol. 2005; 14(Supp123) 33-37.
Satoshi Toyoshima, “Experiment Techniques II”, Hirokawa Publishing Co., 1995, first edition, pp. 110-113.
Non-Final Office Action U.S. Appl. No. 12/030,593 dated Apr. 6, 2010.
Marc Drezner, Reviews in Endocrine & Metabolic Disorders 2001;2: 175-186.
Razzaque et al., Nephrol Dial Transplant, Oct. 2005; 20(10):2032-2035.
Inaba et al., Osteoporos Int. Oct. 2006; 17(10):1506-1513.
Vajdos et al., J. Mol. Biol. Jul. 5, 2002; 320(2):415-428.
Webster's New World Dictionary, Third College Edition, 1988, pp. 1067-1068.
Kobayashi et al., Eur J. Endocrinol. Jan. 2006;154(1)93-99.
Canadian Patent Office Action for 2,418,802 dated Feb. 13, 2009.
First Office Action Chinese Application No. 200810086683.1 dated Mar. 8, 2010.
Human Fibroblast Growth Factor-23 (FGF-23) Elisa Kit 96-Well Plate, EZHFG23-32K, Millipore, Feb. 3, 2009 (17 pgs.).
Human Intact FGF-23 Elisa Kit, Enzyme-Linked ImmunoSorbent Assay (ELISA) for the Determination of Human Fibroblas Growth Factor 23 Levels in Plasma or Cell Culture, 96 Test Kit, Cat. No. 60-6500, Immotopics, Inc., Oct. 2008 (4 pgs.).
Monoclonal Anti-human FGF-23 Antibody, R&D Systems. Cat. No. MAB2604, Apr. 18, 2005.
Monoclanal Anti-human/mouse FGF-23 Antibody, R&D Systems, Cat. No. MAB2629, Sep. 13, 2007.
Monoclonal Anti-mouse FGF-23 Antibody, R&D Systems, Cat. No. MAB26291, Mar. 20, 2007.
Final Office Action for U.S. Appl. No. 10/500,296 dated Apr. 10, 2009.
Non-Final Office Action for U.S. Appl. No. 10/500,296 dated Jul. 24, 2008.
Advisory Action for U.S. Appl. No. 10/500,296 dated Mar. 28, 2008.
Final Office Action for U.S. Appl. No. 10/500,296 dated Oct. 19, 2007.
Non-Final Office Action for U.S. Appl. No. 10/500,296 dated Jan. 30, 2007.
Non-Final Office Action for U.S. Appl. No. 10/500,296 dated Jan. 13, 2006.
Aono et al., “The improving effect of anti FGF23 neutralizing antibody on hypophosphatemia and rickets of Hyp mice”,The Japanese Society for Bone and Mineral Research(JSBMR), Annual Meeting of the JSBMR, 22ndProgram, Aug. 2004, vol. 22, pp. 137. (English translation provided).
Ando, et al.,Tan-Clone-Kotai-Jikken-Manual(“Experimental Manual for Monoclonal Antibody”) (written by and published by Kodansha Scientific, Ltd., Tokyo, Japan (1991).
Antibody Engineering, A Practical Approach, IRL Press, 1996.
Antibody Engineering, A Practical Guide, W.H. Freeman and Company, 1992.
Baker and Worthley, “The Essentials of Calcium, Magnesium and Phosphate Metabolism: Part II. Disorders,”Critical Care&Resuscitation., 2000, vol. 4, pp. 307-315.
Better et al., “Escherichia coliSecretion of an Active Chimeric Antibody Fragment,”Science, May 20, 1998 (nti), vol. 240, pp. 1041-1043.
Bost, et al., “Antibodies Against a Peptide Sequence within the HIV Envelope Protein Crossreacts with Human Interleukin-2”,Immunol. Invest., 1988, vol. 17, Nos. 577-586pp. 577-586.
Bruggemann, et al., “The Immunogenicity of Chimeric Antibodies”,J. Exp. Med., Dec. 1989, vol. 170, No. 6, pp. 2153-2157.
Campbell, A.M.,Monoclonal Antibody Technology, Elsevier Science Publishers, Inc., 1984, pp. 1-32.
Carter, et al., “High LevelEscherichia coliExpression and Production of a Bivalent Humanized Antibody Fragment,”Bio/Technology, 1992, vol. 10, pp. 163-167.
Delves, P. J., “Antibody Production Essential Techniques”,Monoclonal Antibodies, Ed. Shepherd and Dean, Oxford University Press, 2000.
Fishwild, et al., “High-avidity Human IgGκ Monoclonal Antibodies from a Novel Strain of Minilocus Transgenic Mice,”Nat Biotechnol., Jul. 1996, vol. 14, No. 7, pp. 845-851.
Fukagawa, et al., “FGF23: its Role in Renal Bone Disease”,Pediat. Nephrol, 2006, vol. 21, pp. 1802-1806.
Goding, J. W.,Monoclonal Antibodies: Principles and Practice, Academic Press, 1993 and 1995.
Gupta, et al., “FGF-23 is Elevated by Chronic Hyperphosphatemia,”J. Clin. Endocrinol.&Metab., 2004. vol. 89, No. 9, pp. 4489-4492.
Imel, et al., “FGF23 Concentrations Vary with Disease Status in Autosomal Dominant Hypophosphatemic Rickets,”J.of Bone and Mineral Research, 2007, vol. 22, pp. 520-526.
Ishida & Lonberg, IBC's 11th Antibody Engineering, Abstract 2000.
Jonsson, et al., “Fibroblast Growth Factor 23 in Oncogenic Osteomalacia and X-Linked Hypophosphatemia,”N. Engl. J. Med., Apr. 24, 2003, vol. 348, No. 17, pp. 1656-1663.
Karlsson, et al., “Kinetic Analysis of Monoclonal Antibody-Antigen Interactions with a New Biosensor Based Analytical System,”Journal of Immunologic
Fukumoto Seiji
Mizutani Satoru
Shimada Takashi
Yamashita Takeyoshi
Bent Stephen A.
Foley & Lardner LLP
Kyowa Hakko Kirin Co., Ltd.
Saoud Christine J
LandOfFree
Method for treating hypophosphatemic bone diseases using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating hypophosphatemic bone diseases using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating hypophosphatemic bone diseases using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2715487